Evidence mapPaperPMID 36960359Full record

ArticleFrontiers in public health2023

Cost-effectiveness analysis of vaccination against COVID-19 in China.

Huixuan Zhou, Ningxin Ding, Xueyan Han, Hanyue Zhang, Zeting Liu, Xiao Jia, Jingjing Yu, Wei Zhang

Full text read
In one paragraph

Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Huixuan ZhouDepartment of Physical Fitness and Health, School of Sport Science, Beijing Sport University, Beijing, China.
Ningxin DingSchool of Government, Wellington School of Business and Government, Victoria University of Wellington, Wellington, New Zealand.
Xueyan HanSchool of Health Policy and Management, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hanyue ZhangSchool of Physical Education, North East Normal University, Jilin City, China.
Zeting LiuDepartment of Mathematic Science, School of Sport Engineering, Beijing Sport University, Beijing, China.
Xiao JiaKey Laboratory of Exercise and Physical Fitness, Ministry of Education, Beijing Sport University, Beijing, China.
Jingjing YuKey Laboratory of Exercise and Physical Fitness, Ministry of Education, Beijing Sport University, Beijing, China.
Wei ZhangDepartment of Chemical Drug Control, China National Institute for Food and Drug Control, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Since September 2020, Chinese populations aged > 3 years have been encouraged to receive a two-dose inoculation with vaccines against coronavirus disease 2019 (COVID-19). This study aims to evaluate the cost-effectiveness of the current vaccination strategy amongst the general population in mainland China from a societal perspective. Methods: In this study, we construct a decision tree with Markov models to compare the economic and health consequences of the current vaccination strategy versus a no-vaccination scenario, over a time horizon of one year and an annual discount rate of 5%. Transition probabilities, health utilities, healthcare costs, and productivity losses are estimated from literature. Outcome measures include infection rates, death rates, quality-adjusted life years (QALYs), and costs. The incremental cost-effectiveness ratio (ICER) is then calculated to evaluate the cost-effectiveness of the current vaccination strategy, and both one-way deterministic sensitivity analysis and probabilistic sensitivity analysis (PSA) are applied to assess the impact of uncertainties on results. Results: Our simulation indicates that compared with a no-vaccination scenario, vaccination amongst the general population in mainland China would reduce the infection rate from 100% to 45.3% and decrease the death rate from 6.8% to 3.1%. Consequently, the strategy will lead to a saving of 37,664.77 CNY (US$5,256.70) and a gain of 0.50 QALYs per person per year on average (lifetime QALY and productivity loss due to immature death are included). The cost-saving for each QALY gain is 74,895.69 CNY (US$10,452.85). Result of the PSA indicates that vaccination is the dominating strategy with a probability of 97.9%, and the strategy is cost-effective with a probability of 98.5% when the willingness-to-pay (WTP) is 72,000 CNY (US$10,048.71) per QALY. Conclusion: Compared with a no-vaccination scenario, vaccination among the general population in mainland China is the dominating strategy from a societal perspective. The conclusion is considered robust in the sensitivity analyses.

Indexed as

Cost-Effectiveness AnalysisCOVID-19ChinaCost-Benefit AnalysisHumansVaccinationcost-effectiveness analysiscost-utility analysisCOVID-19SARS-CoV-2vaccination

Identifiers

PMID36960359
PMCPMC10027744

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read46
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.